P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (5th April 2022) - Usmani, S; Alonso, A; Quach, H; Koh, Y; Guenther, A; Min, CK; Leleu, X; Abdallah, AO; Oriol, A; Bessemer, B; Garg, M; Sandhu, I; et al.